| Population 2013 |
47 million |
| |
| | | | | |
| Estimates of TB burden * 2013 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
0.24 |
(0.23–0.24) |
0.51 |
(0.5–0.51) |
| Mortality (HIV+TB only) |
0.049 |
(0.023–0.085) |
0.1 |
(0.05–0.18) |
| Prevalence (includes HIV+TB) |
7.3 |
(3.1–13) |
16 |
(6.5–28) |
| Incidence (includes HIV+TB) |
6.1 |
(5.8–6.8) |
13 |
(12–15) |
| Incidence (HIV+TB only) |
0.53 |
(0.39–0.67) |
1.1 |
(0.83–1.4) |
| Case detection, all forms (%) |
86 |
(77–90) |
|
|
| |
| | | | | |
| Estimates of MDR-TB burden * 2013 |
|
New |
|
Retreatment |
| % of TB cases with MDR-TB |
0.22 |
(0.03–0.8) |
7.1 |
(3.3–13) |
MDR-TB cases among notified pulmonary
TB cases |
8 |
(1–30) |
21 |
(10–39) |
| |
| | | | | |
| TB case notifications 2013 |
New ** |
Relapse |
| Pulmonary, bacteriologically confirmed |
3 042 |
|
0 |
| Pulmonary, clinically diagnosed |
719 |
|
0 |
| Extrapulmonary |
1 483 |
|
0 |
| |
|
|
|
| Total new and relapse |
5 244 |
|
|
| Previously treated, excluding relapses |
295 |
|
|
| Total cases notified |
5 539 |
|
|
| |
| | | | | |
| Among 5 233 new and relapse cases: | | | | | |
| 377 (7%) cases aged under 15 years; male:female ratio: 1.5 | | | |
| | | | | |
| Reported cases of RR-/MDR-TB 2013 |
New |
Retreatment |
Total ** |
| Cases tested for RR-/MDR-TB |
1 458 (48%) |
103 (35%) |
1 561 |
| Laboratory-confirmed RR-/MDR-TB cases |
|
|
42 |
| Patients started on MDR-TB treatment |
|
|
|
| |
| | | | | |
| TB/HIV 2013 |
Number |
(%) |
| TB patients with known HIV status |
4 065 |
(73) |
| HIV-positive TB patients |
273 |
(7) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |
|
|
| HIV-positive TB patients on antiretroviral therapy (ART) |
|
|
| HIV-positive people screened for TB |
|
|
| HIV-positive people provided with IPT |
|
|
| |
| | | | | |
| Treatment success rate |
(%) |
| New and relapse cases registered in 2012 |
71 |
| Previously treated cases, excluding relapse, registered in 2012 |
60 |
| HIV-positive TB cases, all types, registered in 2012 |
60 |
| RR-/MDR-TB cases started on second-line treatment in 2011 |
|
| XDR-TB cases started on second-line treatment in 2011 |
|
| |
| | | | | |
| Laboratories 2013 |
|
| Is second-line drug susceptibility testing available? |
Yes, in country |
| |
| | | | | |
| Financing TB control 2014 |
|
| National TB programme budget (US$ millions) |
|
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | |
| ** Includes cases with unknown previous TB treatment history | | |
| | | | | |